This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
COTY Pulls Up Q1 View on Solid Demand for Beauty & Skin Care
by Zacks Equity Research
COTY is seeing solid beauty demand in the near term, pushing management to raise its first-quarter fiscal 2023 view. It expects to double skincare revenues by fiscal 2025.
Philip Morris (PM) Benefits From Focus on RRPs & Pricing Power
by Zacks Equity Research
Philip Morris (PM) is well placed to become a majority smoke-free company by 2025. The company has long been benefiting from its strong pricing power.
Helen of Troy (HELE) Down More Than 45% in 6 Months: Here's Why
by Zacks Equity Research
Helen of Troy (HELE) is battling headwinds like a shift in consumer buying patterns, inflation, supply-chain disruptions and unfavorable currency.
Zacks.com featured highlights include Inter Parfums, PBF Energy and Kroger
by Zacks Equity Research
Inter Parfums, PBF Energy and Kroger have been highlighted in this Screen of The Week article.
The Estee Lauder Companies (EL) Online Business Aids Growth
by Zacks Equity Research
The Estee Lauder Companies (EL) online operations and Skin Care business bode well. However, the company is witnessing inflation and supply chain disruptions.
Buy These 3 Top Stocks Now for Solid Earnings Growth
by Tirthankar Chakraborty
Invest in stocks like Inter Parfums (IPAR), PBF Energy (PBF) & Kroger (KR) at the moment for superb earnings growth.
COTY Poised on Strategic Pillars & Cost Saving Efforts
by Zacks Equity Research
COTY is benefiting from its focus on six strategic pillars aimed at sustainable growth. Management is on track to mitigate the impact of inflation via cost savings.
Nu Skin (NUS) Down More Than 15% in 3 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is battling continued economic uncertainty, prolonged COVID-associated factors, unfavorable currency rates and geopolitical conflicts.
COTY Q4 Loss In Line With Estimates, Sales Increase Y/Y
by Zacks Equity Research
COTY fourth-quarter fiscal 2022 results reflect improved top and bottom lines on growth across almost all regions and channels. Focus on strategic growth pillars is yielding.
The Estee Lauder Companies (EL) Beats on Earnings in Q4
by Zacks Equity Research
The Estee Lauder Companies' (EL) fourth-quarter fiscal 2022 sales and earnings decline year over year on softness in almost all regions. Rising inflation and supply chain disruptions pose a threat.
Helen of Troy (HELE) Hurt by Cost Inflation, Down 24% in 3 Months
by Zacks Equity Research
Helen of Troy (HELE) is grappling with cost inflation and supply chain headwinds. It is also bearing the brunt of reduced consumer demand and shifts in consumer spending patterns.
Inter Parfums (IPAR) Q2 Earnings Miss Estimates, Sales Rise Y/Y
by Zacks Equity Research
Inter Parfums' (IPAR) second-quarter 2022 results reflect higher earnings and sales on growth across European and U.S.-based operations.
Inter Parfums (IPAR) Misses Q2 Earnings Estimates
by Zacks Equity Research
Inter Parfums (IPAR) delivered earnings and revenue surprises of -12.24% and 0.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inter Parfums (IPAR) Readies for Q2 Earnings: Things to Note
by Zacks Equity Research
Inter Parfums' (IPAR) second-quarter 2022 results are likely to reflect solid sales due to a rise in Europe-based and U.S.-based product sales. Cost inflation and supply-chain woes are likely to have been concerns.
Clorox (CLX) Falls on Q4 Earnings & Sales Miss, Bleak View
by Zacks Equity Research
Clorox's (CLX) Q4 results reflect the impacts of lower shipments, higher tax rate and continued costs headwinds related to elevated manufacturing and logistics costs, and higher commodity costs.
Inter Parfums (IPAR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Inter Parfums (IPAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Top-Rated Stocks to Invest in for Attractive Earnings Growth
by Tirthankar Chakraborty
Invest in stocks like Inter Parfums (IPAR), Carlisle Companies (CSL) & Franklin Electric (FELE) for superb earnings growth.
Inter Parfums (IPAR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Inter Parfums (IPAR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Inter Parfums (IPAR) Ups 2022 Guidance on Robust Q2 Sales
by Zacks Equity Research
Inter Parfums' (IPAR) sales increase year over year in second-quarter 2022. Management raises its top-and bottom-line view for 2022.
Inter Parfums (IPAR) Partners With G-III Apparel to Fuel Growth
by Zacks Equity Research
Inter Parfums (IPAR) finalizes an agreement with G-III Apparel to become the exclusive worldwide licensee for the Donna Karan and DKNY fragrance brands.
Inter Parfums (IPAR) Gains on Solid Brands & Partnerships
by Zacks Equity Research
Inter Parfums (IPAR) is benefiting from strength in its brand portfolio. The company's focus on product launches to boost assortment strength is impressive.
Revlon (REV) Stock Jumps 62.5%: Will It Continue to Soar?
by Zacks Equity Research
Revlon (REV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Inter Parfums (IPAR) Q1 Earnings Top Estimates, Sales Rise Y/Y
by Zacks Equity Research
Inter Parfums' (IPAR) first-quarter 2022 results reflect higher earnings and sales on growth across European and U.S.-based operations.
Inter Parfums (IPAR) Tops Q1 Earnings Estimates
by Zacks Equity Research
Inter Parfums (IPAR) delivered earnings and revenue surprises of 17.02% and 0.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
International Flavors (IFF) Q1 Earnings Top Estimates, View Up
by Zacks Equity Research
International Flavors' (IFF) Q1 top line gains from solid growth in Health & Biosciences, Nourish and Pharma Solutions and additional sales related to the merger with N&B business.